Sources

9 Total Sources

Merck Says Tulisokibart Hits Phase 3 UC Goals at 12 Weeks

Left50%

Center50%

Merck's Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis

StockTitan5h ago

Merck's tulisokibart hits Phase 3 UC endpoints | MRK Stock News

pharmatutor.org5h ago

Merck's Tulisokibart Clears Key Phase 3 Hurdle, Raising Hopes for Ulcerative Colitis Patients

Marketscreener.com5h ago

Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study | MarketScreener

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - BioSpace

New Castle News5h ago

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | National | ncnewsonline.com

GuruFocus.com5h ago

Merck (MRK) Reports Promising Phase 3 Study Results for Tulisoki

富途牛牛5h ago

Merck Experimental Ulcerative Colitis Drug Meets Primary Endpoint in Phase 3 Trial

MD Magazine5h ago

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A | HCPLive